Book Appointment Now
Letter To Editor Series
THE L2E MASTERCLASS
Publish Your First Letter to the Editor
A short, practical walkthrough to move from idea to accepted fast. Follow our three simple steps below.
STEP 1: UNDERSTAND THE GAME
Learn the Fundamentals
First, get the complete overview. This session covers the writing workflow, how to pick the right journal, and the critical skill of avoiding predatory publishers.
STEP 2: SEE A REAL EXAMPLE
Watch a First Draft in Action
Next, watch a student present her actual first draft. This shows you the real, unfiltered starting point for a Letter to the Editor and sets the stage for feedback.
STEP 3: LEARN FROM FEEDBACK
Master the Art of Revision
Finally, see how a mentor gives constructive feedback on the draft from Step 2. This is the most crucial part of learning—turning good ideas into a great, publishable letter.
Ready to Take Action?
You've completed the training—now it's your turn to write. Join our free WhatsApp community to share drafts, ask questions, and get support from peers and mentors.
Understanding Research Paper Structure
A Guide to Crafting the Title & Author Section
From Draft to Dialogue: A Living Review
Watch the mentorship process unfold. We'll automatically highlight parts of the student's draft and show the mentor's feedback. Hover or hold to pause the animation. Read the student's draft and tap the underlined phrases to reveal the mentor's feedback.
Student's First Draft
By Sakshi Rajendra Singh Bundeli
To the Editor,
Sir/ Madam Ozempic is a drug composed of semaglutide a GLP-1 receptor agonist initially used as an antidiabetic medication now gained popularity after it was approved by FDA for the purpose of weight loss. (1,2).
This drug is known to work by increasing insulin release and decreasing glucagon release for the treatment of diabetes, and acts on the hypothalamus to decrease hunger and increase satiety along with decreasing gastric emptying for the treatment of weight loss (3).
Weekly subcutaneous injection of this drug has shown significant weight loss (4). Currently semaglutide is marketed for weight loss under a number of brand names besides Ozempic.
According to an analysis published in 2022 which was conducted using data from FDA’s adverse event reporting system semaglutide is associated with less severe adverse gastrointestinal events like nausea, vomiting, diarrhea, constipation, etc as well as more serious adverse effects including pancreatitis (5).
Semaglutide is the 2nd most common GLP-1 receptor agonist which is associated with pancreatitis and must be avoided in patients at risk for it (6). However, there is not enough information to draw the conclusion that one of the most frequent side effects of semaglutide medication is pancreatitis.
With its enormous population and increasing obesity rates, India is at risk of drug misuse involving substances akin to Ozempic, such as the oral Rybelsus and the injectable, obesity-specific Wegovy. These drugs can potentially be used off-label and are endorsed by celebrities on social media (7,8).
This drug is now a part of discussion among peers and can be viewed as a shortcut to lose weight. However, off label use without professional guidance can lead to serious adverse effects like pancreatitis. It is important to study the long-term effects of these drugs among non-diabetic populations and educate patients about lifestyle modification as the primary approach for weight management.
Mentor's Live Feedback
The review animates below. You can also reveal all feedback at once.
Ready to Level Up Your Research?
A Letter to the Editor is a fantastic start. When you're ready to tackle more complex projects like systematic reviews, having the right tools is essential.